Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duoenyi + Capecitabine in Advanced Biliary Tract Carcinoma
NCT06430827Phase 2Not yet recruiting
- Sponsor
- Bayi Biopharma
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in biliary tract carcinoma (BTC), sponsored by Bayi Biopharma. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT06430827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430827.